Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PFE 
Pfizer Inc (PFE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: PFE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $28.81
1 Year Target Price $28.81
| 7 | Strong Buy |
| 2 | Buy |
| 15 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.63% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 138.10B USD | Price to earnings Ratio 12.85 | 1Y Target Price 28.81 |
Price to earnings Ratio 12.85 | 1Y Target Price 28.81 | ||
Volume (30-day avg) 25 | Beta 0.47 | 52 Weeks Range 20.18 - 27.69 | Updated Date 10/30/2025 |
52 Weeks Range 20.18 - 27.69 | Updated Date 10/30/2025 | ||
Dividends yield (FY) 6.94% | Basic EPS (TTM) 1.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When Before Market | Estimate 0.64 | Actual - |
Profitability
Profit Margin 16.84% | Operating Margin (TTM) 28.68% |
Management Effectiveness
Return on Assets (TTM) 5.25% | Return on Equity (TTM) 12.17% |
Valuation
Trailing PE 12.85 | Forward PE 8.67 | Enterprise Value 201641707540 | Price to Sales(TTM) 2.16 |
Enterprise Value 201641707540 | Price to Sales(TTM) 2.16 | ||
Enterprise Value to Revenue 3.16 | Enterprise Value to EBITDA 10.01 | Shares Outstanding 5685550500 | Shares Floating 5675828209 |
Shares Outstanding 5685550500 | Shares Floating 5675828209 | ||
Percent Insiders 0.07 | Percent Institutions 67.2 |
Upturn AI SWOT
Pfizer Inc
Company Overview
History and Background
Pfizer Inc. was founded in 1849 in New York City by Charles Pfizer and Charles Erhart. Initially producing fine chemicals, it expanded into pharmaceuticals and grew through innovation and strategic acquisitions, becoming a global leader in the industry.
Core Business Areas
- Biopharmaceuticals: Focuses on the development, manufacturing, and commercialization of innovative medicines and vaccines, including treatments for cancer, cardiovascular diseases, and immune disorders.
Leadership and Structure
Albert Bourla serves as the Chairman and CEO. The organizational structure includes various business units and functional departments reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): A mRNA-based vaccine developed in partnership with BioNTech. While market share fluctuates, it holds a significant portion of the COVID-19 vaccine market. Competitors include Moderna (MRNA), Novavax (NVAX), and various vaccines from other countries.
- Prevnar Family (Pneumococcal Vaccines): Vaccines to prevent pneumococcal disease. Prevnar 13 held significant market share and Prevnar 20 continues in a similar position. Competitors include Merck (MRK) with Pneumovax 23.
- Eliquis (Anticoagulant): An anticoagulant used to prevent blood clots. Pfizer co-markets Eliquis with Bristol Myers Squibb (BMY). Competitors include Xarelto (JNJ) and other anticoagulants.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, strict regulatory requirements, and intense competition. Key trends include personalized medicine, biosimilars, and digital health.
Positioning
Pfizer is a leading global pharmaceutical company with a strong pipeline of innovative products and a broad global presence. Its competitive advantages include its research capabilities, established brands, and extensive distribution network.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Pfizer is positioned to capture a significant portion of this TAM through its diverse portfolio and strategic investments.
Upturn SWOT Analysis
Strengths
- Strong financial performance
- Diversified product portfolio
- Global presence
- Robust R&D pipeline
- Established brand recognition
Weaknesses
- Reliance on key products
- Patent expirations
- Exposure to generic competition
- High R&D costs
- Dependence on regulatory approvals
Opportunities
- Emerging markets growth
- New product development
- Strategic acquisitions
- Expansion into biosimilars
- Advancements in biotechnology
Threats
- Pricing pressures
- Regulatory changes
- Generic competition
- Product liability litigation
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- ABBV
- BMY
- LLY
- NVO
Competitive Landscape
Pfizer faces intense competition from other large pharmaceutical companies. Its advantages include its diversified portfolio and global reach, but it faces challenges from generic competition and pricing pressures.
Major Acquisitions
Arena Pharmaceuticals
- Year: 2022
- Acquisition Price (USD millions): 6700
- Strategic Rationale: Expand Pfizer's pipeline in gastroenterology, dermatology, and cardiology.
Growth Trajectory and Initiatives
Historical Growth: Pfizer's growth has been driven by acquisitions, new product launches, and global expansion.
Future Projections: Analysts project moderate growth for Pfizer, driven by its pipeline and strategic initiatives.
Recent Initiatives: Pfizer has focused on strategic acquisitions, partnerships, and investments in R&D to drive future growth.
Summary
Pfizer is a strong global pharmaceutical company with a diversified portfolio and robust R&D pipeline. While its performance is impacted by patent expirations and competition, strategic acquisitions and product launches drive growth. The company should be mindful of evolving regulations and healthcare trends while pursuing growth opportunities in emerging markets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Materials
- Market Research Reports
- Analyst Estimates
- Stock Charts (StockCharts.com)
- Bloomberg
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pfizer Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2012-08-13 | Chairman of the Board & CEO Dr. Albert Bourla D.V.M., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 81000 | Website https://www.pfizer.com |
Full time employees 81000 | Website https://www.pfizer.com | ||
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.